Northern Trust Corp Fibrogen Inc Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Fibrogen Inc stock. As of the latest transaction made, Northern Trust Corp holds 176,955 shares of FGEN stock, worth $60,164. This represents 0.0% of its overall portfolio holdings.

Number of Shares

176,955

Previous 686,527 74.22%

Holding current value

$60,164

Previous $611,000 88.54%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.33 - $1.26 $168,158 - $642,060	-509,572 Reduced 74.22%	176,955 $70,000
Q2 2024 Aug 14, 2024	SELL	$0.89 - $2.36 $62,267 - $165,115	-69,964 Reduced 9.25%	686,527 $611,000
Q1 2024 May 14, 2024	SELL	$0.73 - $2.73 $15,294 - $57,198	-20,952 Reduced 2.69%	756,491 $1.78 Million
Q4 2023 Feb 13, 2024	BUY	$0.38 - $0.91 $14,160 - $33,911	37,265 Added 5.03%	777,443 $691,000
Q3 2023 Nov 13, 2023	SELL	$0.79 - $2.83 $80,230 - $287,406	-101,557 Reduced 12.07%	740,178 $636,000
Q2 2023 Aug 11, 2023	BUY	$2.49 - $20.59 $13,846 - $114,500	5,561 Added 0.67%	841,735 $2.27 Million
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $275,839 - $435,462	17,294 Added 2.11%	836,174 $15.6 Million
Q4 2022 Feb 13, 2023	BUY	$13.27 - $17.73 $271,663 - $362,968	20,472 Added 2.56%	818,880 $13.1 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $72,344 - $92,651	-6,346 Reduced 0.79%	798,408 $10.4 Million
Q2 2022 Aug 12, 2022	SELL	$7.94 - $12.96 $336,624 - $549,452	-42,396 Reduced 5.0%	804,754 $8.5 Million
Q1 2022 May 13, 2022	SELL	$12.02 - $16.79 $767,681 - $1.07 Million	-63,867 Reduced 7.01%	847,150 $10.2 Million
Q4 2021 Feb 08, 2022	BUY	$9.93 - $15.39 $375,185 - $581,480	37,783 Added 4.33%	911,017 $12.8 Million
Q3 2021 Nov 15, 2021	SELL	$10.18 - $26.64 $297,826 - $779,379	-29,256 Reduced 3.24%	873,234 $8.92 Million
Q2 2021 Aug 13, 2021	SELL	$18.57 - $35.68 $1.09 Million - $2.09 Million	-58,701 Reduced 6.11%	902,490 $24 Million
Q1 2021 May 12, 2021	SELL	$31.0 - $55.72 $2.53 Million - $4.55 Million	-81,576 Reduced 7.82%	961,191 $33.4 Million
Q4 2020 Feb 11, 2021	SELL	$37.09 - $48.97 $1.35 Million - $1.78 Million	-36,292 Reduced 3.36%	1,042,767 $38.7 Million
Q3 2020 Nov 16, 2020	BUY	$40.47 - $45.5 $657,354 - $739,056	16,243 Added 1.53%	1,079,059 $44.4 Million
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $931,827 - $1.23 Million	28,610 Added 2.77%	1,062,816 $43.1 Million
Q1 2020 May 14, 2020	BUY	$23.3 - $45.96 $255,973 - $504,916	10,986 Added 1.07%	1,034,206 $35.9 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $336,325 - $467,431	-9,726 Reduced 0.94%	1,023,220 $43.9 Million
Q3 2019 Nov 13, 2019	BUY	$36.98 - $48.45 $1.4 Million - $1.83 Million	37,867 Added 3.81%	1,032,946 $38.2 Million
Q2 2019 Aug 13, 2019	BUY	$35.13 - $55.53 $2.01 Million - $3.18 Million	57,248 Added 6.1%	995,079 $45 Million
Q1 2019 May 13, 2019	BUY	$42.83 - $59.91 $802,848 - $1.12 Million	18,745 Added 2.04%	937,831 $51 Million
Q4 2018 Feb 12, 2019	BUY	$37.97 - $60.16 $76,813 - $121,703	2,023 Added 0.22%	919,086 $42.5 Million
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $775,645 - $926,503	13,777 Added 1.53%	917,063 $55.7 Million
Q2 2018 Sep 18, 2018	SELL	$44.9 - $64.95 $228,002 - $329,816	-5,078 Reduced 0.56%	903,286 $56.5 Million
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $3.48 Million - $5.03 Million	77,426 Added 9.32%	908,364 $56.9 Million
Q1 2018 May 09, 2018	SELL	$45.35 - $61.65 $283,074 - $384,819	-6,242 Reduced 0.75%	830,938 $38.4 Million
Q4 2017 Feb 14, 2018	BUY	$41.95 - $60.1 $519,047 - $743,617	12,373 Added 1.5%	837,180 $39.7 Million
Q3 2017 Nov 13, 2017	BUY	$33.4 - $53.9 $27.5 Million - $44.5 Million	824,807	824,807 $44.4 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Fibrogen Inc Transaction History